Abstract:As a glycol-protein located in extracellular matrix (ECM), tenascin-C (TNC) is absent in most normal adult tissues but is highly expressed in the majority of malignant solid tumors. Pancreatic cancer is characterized by an abundant fibrous tissue rich in TNC. Although it was reported that TNC's expression increased in the progression from low-grade precursor lesions to invasive cancer and was associated with tumor differentiation in human pancreatic cancer, studies on the relations between TNC and tumor progression in pancreatic cancer were rare. In this study, we performed an analysis to determine the effects of TNC on modulating cell apoptosis and chemo-resistance and explored its mechanisms involving activation in pancreatic cancer cell. The expressions of TNC, ERK1/2/p-ERK1/2, Bcl-xL and Bcl-2 were detected by immunohistochemistry and western blotting. Then the effects of exogenous and endogenous TNC on the regulation of tumor proliferation, apoptosis and gemcitabine cytotoxicity were investigated. The associations among the TNC knockdown, TNC stimulation and expressions of ERK1/2/NF-κB/p65 and apoptotic regulatory proteins were also analyzed in cell lines. The mechanism of TNC on modulating cancer cell apoptosis and drug resistant through activation of ERK1/2/NF-κB/p65 signals was evaluated. The effect of TNC on regulating cell cycle distribution was also tested. TNC, ERK1/2/p-ERK1/2, and apoptotic regulatory proteins Bcl-xL and Bcl-2 were highly expressed in human pancreatic cancer tissues. In vitro, exogenous TNC promoted pancreatic cancer cell growth also mediates basal as well as starved and drug-induced apoptosis in pancreatic cancer cells. The effects of TNC on anti-apoptosis were induced by the activation state of ERK1/2/NF-κB/p65 signals in pancreatic cell. TNC phosphorylate ERK1/2 to induce NF-κB/p65 nucleus translocation. The latter contributes to promote Bcl-xL, Bcl-2 protein expressions and reduce caspase activity, which inhibit cell apoptotic processes. TNC mediated gemcitabine chemo-resistance via modulating cell apoptosis in pancreatic cancer. TNC resulted in the enrichment of pancreatic cancer cells in S-phase with a concomitant decrease in number of cells in G1 phase. The present study indicated TNC in cellular matrix induces an activation of ERK1/2/NF-κB/p65 signaling cascade and thereby mediates resistance to apoptosis in pancreatic cancer. TNC could serve as a diagnostic marker and predictor of gemcitabine response and potentially as a target for chemotherapy of pancreatic cancer.

Cmtm5 Induces Apoptosis of Pancreatic Cancer Cells and Has Synergistic Effects with Tnf-Alpha

PRMT5 Promotes Epithelial‐mesenchymal Transition Via EGFR‐β‐catenin Axis in Pancreatic Cancer Cells

CMTM5-v1 induces apoptosis in cervical carcinoma cells.

CMTM5 Exhibits Tumor Suppressor Activities and is Frequently Silenced by Methylation in Carcinoma Cell Lines

CMTM5 Exhibits Tumor Suppressor Activity Through Promoter Methylation in Oral Squamous Cell Carcinoma

CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo

CXCL5 knockdown attenuated gemcitabine resistance of pancreatic cancer through regulation of cancer cells and tumour stroma.

Prognostic Implications of Pan-cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment

Effect of CMTM5 on Prostate Cancer Cell Proliferation, Migration and Invasion

Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia

Research advances in CKLF-like MARVEL transmembrane domain containing member 5]

CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells

CXCL5 Promotes the Malignant Phenotype of Pancreatic Cancer and Is Associated With Immune Infiltration

Data from <i>CMTM3</i>, Located at the Critical Tumor Suppressor Locus 16q22.1, Is Silenced by CpG Methylation in Carcinomas and Inhibits Tumor Cell Growth through Inducing Apoptosis

Aberrant expression of TCTP protein inhibits cell apoptosis by up-regulating Bcl-xL in human pancreatic cancer

MicroRNA-216b-5p Functions as a Tumor-suppressive RNA by Targeting TPT1 in Pancreatic Cancer Cells

PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis

Tenascin-C Induces Resistance to Apoptosis in Pancreatic Cancer Cell Through Activation of ERK/NF-κB Pathway.

Cmtm3, Located At The Critical Tumor Suppressor Locus 16q22.1, Is Silenced By Cpg Methylation In Carcinomas And Inhibits Tumor Cell Growth Through Inducing Apoptosis

Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity

[CMTM5 Inhibits the Tumor Cell Behavior of Prostate Cancer by Downregulation of HER2].